|Lamivudine||nucleoside reverse transcriptase inhibitor|
|Nevirapine||non-nucleoside reverse transcriptase inhibitor|
|Zidovudine||nucleoside reverse transcriptase inhibitor|
|Trade names||Duovir-N, Zidovex-LN, others|
|Defined daily dose||not established|
Lamivudine/nevirapine/zidovudine (3TC/NVP/AZT) is a fixed-dose combination medication used to treat HIV/AIDS. It contains lamivudine, nevirapine, and zidovudine. It is either used by itself or along with other antiretrovirals. It is a recommended treatment in those who are pregnant. It is taken by mouth twice a day.
The medication is generally well tolerated. Side effects are those of the underlying medications. This includes rash, pancreatitis, low white blood cell levels, and muscle pain. Use is not recommended in those with significant liver problems. Use in pregnancy and breastfeeding appear to be safe. The combination tablet is typically not appropriate for children.
It is on the World Health Organization's List of Essential Medicines. The wholesale cost in the developing world is about 8.54 to 18.94 USD a month as of 2014. The combination is not commercially available in the United States as of 2018.
- "Nevirapine, zidovudine and lamivudine" (PDF). aidsmap. Archived from the original (PDF) on 20 December 2016. Retrieved 18 December 2016. CS1 maint: discouraged parameter (link)
- "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 18 September 2020. CS1 maint: discouraged parameter (link)
- World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. pp. 157, 161. hdl:10665/44053. ISBN 9789241547659.
- World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- "Lamivudine + Zidovudine + Nevirapine". International Drug Price Indicator Guide. Retrieved 8 December 2016. CS1 maint: discouraged parameter (link)
- "Drugs@FDA: FDA Approved Drug Products". www.accessdata.fda.gov. Retrieved 6 January 2018. CS1 maint: discouraged parameter (link)